- AU$49.30m
- AU$46.31m
- AU$14.12m
- 96
- 38
- 34
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.64 | ||
| Price to Tang. Book | 126.4 | ||
| Price to Free Cashflow | 33.35 | ||
| Price to Sales | 3.49 | ||
| EV to EBITDA | 13.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.72% | ||
| Return on Equity | 98.18% | ||
| Operating Margin | 17.68% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 10.02 | 11.76 | 11.94 | 12.61 | 14.12 | n/a | n/a | 9.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +0.58 | +100.65 | +3.29 | +30.59 | +0.32 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cryosite Limited is engaged in providing outsourced clinical trials depot services. The Company manages the entire clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution and reverse logistics management. Its segments include Ambient, Cold, and Frozen, Ultra Frozen and Cryogenic and Cord blood. The Ambient, Cold, and Frozen segment storages and distributes small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions. Ultra Frozen and Cryogenic is engaged in specialized handling of materials requiring Ultra-Frozen or Cryogenic conditions, including Advanced Therapy Medicinal Products (ATMPs), such as Cell and Gene Therapies (CGT), cell therapies, and others. The cord blood segment is engaged in storage of cord blood cell and tissue samples for personal or directed therapeutic use, maintained under validated chain-of-identity controls.
Directors
- Bryan Dulhunty CHM
- John Hogg CEO
- Kim Bradley SEC
- Andrew Kroger NED
- Nicola Swift NED (52)
- Steven Waller NED
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- December 14th, 1999
- Public Since
- May 9th, 2002
- No. of Shareholders
- 471
- No. of Employees
- 25
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 48,809,563
- Address
- 13a Ferndell St, South granville, SYDNEY, 2142
- Web
- https://www.cryosite.com/
- Phone
- +61 288652000
- Auditors
- Forvis Mazars Audit & Assurance Pty Limited
Upcoming Events for CTE
Similar to CTE
Apiam Animal Health
Australian Stock Exchange - SEATS
Artrya
Australian Stock Exchange - SEATS
Australian Clinical Labs
Australian Stock Exchange - SEATS
Cann
Australian Stock Exchange - SEATS
Careteq
Australian Stock Exchange - SEATS
FAQ
What is the Cryosite share price?
As of Today at 10:08 UTC, shares in Cryosite are trading at AU$1.01. This share price information is delayed by 15 minutes.
How has the Cryosite share price performed this year?
Shares in Cryosite last closed at AU$1.01 and the price had moved by +26.25% over the past 365 days. In terms of relative price strength the Cryosite share price has outperformed the ASX All Ordinaries Index by +20.68% over the past year.
What are the analyst and broker recommendations for Cryosite?
There is no consensus recommendation for this security.
Find out moreWhat is the Cryosite dividend yield?
Cryosite does not currently pay a dividend.
Does Cryosite pay a dividend?
Cryosite does not currently pay a dividend.
When does Cryosite next pay dividends?
Cryosite does not currently pay a dividend.
How do I buy Cryosite shares?
To buy shares in Cryosite you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cryosite?
As of the previous close price of AU$1.01, shares in Cryosite had a market capitalisation of AU$49.30m.
Where are Cryosite shares listed?
Here are the trading details for Cryosite:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CTE
What kind of share is Cryosite?
Based on an overall assessment of its quality, value and momentum Cryosite is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cryosite share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Cryosite share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cryosite. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +32.43%.
As of the last closing price of AU$1.01, shares in Cryosite were trading +15.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cryosite PE Ratio?
The Cryosite PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cryosite?
Cryosite's management team is headed by:
- Bryan Dulhunty - CHM
- John Hogg - CEO
- Kim Bradley - SEC
- Andrew Kroger - NED
- Nicola Swift - NED
- Steven Waller - NED